MCRB
Income statement / Annual
Last year (2024), Seres Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Seres Therapeutics, Inc.'s net income was $136.00 K.
See Seres Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$144.93 M |
$33.22 M |
$34.51 M |
$28.27 M |
$32.10 M |
$21.77 M |
$0.00 |
| Cost of Revenue |
$3.53 M
|
$0.00
|
$0.00
|
$0.00
|
$90.57 M
|
$0.00
|
$95.96 M
|
$89.46 M
|
$81.99 M
|
$728.00 K
|
| Gross Profit |
-$3.53 M
|
$0.00
|
$0.00
|
$144.93 M
|
-$57.36 M
|
$34.51 M
|
-$67.69 M
|
-$57.36 M
|
-$60.22 M
|
-$728.00 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
1
|
-1.73
|
1
|
-2.39
|
-1.79
|
-2.77
|
0
|
| Research and Development Expenses |
$64.60 M
|
$117.60 M
|
$109.65 M
|
$141.89 M
|
$90.57 M
|
$80.14 M
|
$95.96 M
|
$89.46 M
|
$81.99 M
|
$38.10 M
|
| General & Administrative Expenses |
$53.18 M
|
$77.50 M
|
$70.26 M
|
$69.26 M
|
$30.78 M
|
$24.75 M
|
$32.60 M
|
$34.04 M
|
$32.62 M
|
$16.76 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$53.18 M
|
$77.50 M
|
$70.26 M
|
$69.26 M
|
$30.78 M
|
$24.75 M
|
$32.60 M
|
$34.04 M
|
$32.62 M
|
$16.76 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
-$1.73 M
|
-$90.57 M
|
$1.49 M
|
$170.00 K
|
$425.00 K
|
$0.00
|
$0.00
|
| Operating Expenses |
$117.78 M
|
$195.10 M
|
$179.91 M
|
$209.42 M
|
$30.78 M
|
$106.38 M
|
$128.55 M
|
$123.50 M
|
$114.61 M
|
$54.86 M
|
| Cost And Expenses |
$121.32 M
|
$195.10 M
|
$179.91 M
|
$209.42 M
|
$121.35 M
|
$106.38 M
|
$128.55 M
|
$123.50 M
|
$114.61 M
|
$54.86 M
|
| Interest Income |
$3.97 M
|
$7.30 M
|
$3.06 M
|
$2.87 M
|
$946.00 K
|
$1.03 M
|
$0.00
|
$0.00
|
$2.23 M
|
$638.00 K
|
| Interest Expense |
$0.00
|
$13.18 M
|
$6.02 M
|
$2.91 M
|
$2.92 M
|
$502.00 K
|
$1.17 M
|
$1.59 M
|
$969.00 K
|
$555.00 K
|
| Depreciation & Amortization |
$5.47 M
|
$6.24 M
|
$6.63 M
|
$5.95 M
|
$8.89 M
|
$7.60 M
|
$7.86 M
|
$7.26 M
|
$4.21 M
|
$728.00 K
|
| EBITDA |
-$120.30 M |
-$181.42 M |
-$170.93 M |
-$56.72 M |
-$77.31 M |
-$62.17 M |
-$91.08 M |
-$82.12 M |
-$88.63 M |
-$54.13 M |
| EBITDA Ratio |
0
|
0
|
0
|
-0.39
|
-2.33
|
-1.8
|
-3.22
|
-2.56
|
-4.07
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
-0.45
|
-2.65
|
-2.08
|
-3.55
|
-2.85
|
-4.27
|
0
|
| Total Other Income/Expenses Net |
-$4.46 M
|
$4.97 M
|
-$3.67 M
|
-$1.09 M
|
-$997.00 K
|
$1.60 M
|
$1.34 M
|
$2.02 M
|
$1.26 M
|
$76.00 K
|
| Income Before Tax |
-$125.77 M
|
-$190.13 M
|
-$183.58 M
|
-$65.58 M
|
-$89.13 M
|
-$70.28 M
|
-$98.94 M
|
-$89.38 M
|
-$91.58 M
|
-$54.78 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
-0.45
|
-2.68
|
-2.04
|
-3.5
|
-2.78
|
-4.21
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
$136.00 K
|
-$113.72 M
|
-$250.16 M
|
-$65.58 M
|
-$89.13 M
|
-$70.28 M
|
-$98.94 M
|
-$89.38 M
|
-$91.58 M
|
-$54.78 M
|
| Net Income Ratio |
0
|
0
|
0
|
-0.45
|
-2.68
|
-2.04
|
-3.5
|
-2.78
|
-4.21
|
0
|
| EPS |
-18.8636 |
-17.769 |
-46.2924 |
-14.3022 |
-22.3406 |
-24.812 |
-48.5682 |
-44.1934 |
-46 |
-46.6 |
| EPS Diluted |
-18.8636 |
-17.769 |
-46.2924 |
-14.3022 |
-22.3406 |
-24.812 |
-48.5682 |
-44.1934 |
-46 |
-46.6 |
| Weighted Average Shares Out |
$7.77 M
|
$6.40 M
|
$5.40 M
|
$4.59 M
|
$3.99 M
|
$2.83 M
|
$2.04 M
|
$2.02 M
|
$1.99 M
|
$1.18 M
|
| Weighted Average Shares Out Diluted |
$7.77 M
|
$6.40 M
|
$5.40 M
|
$4.59 M
|
$3.99 M
|
$2.83 M
|
$2.04 M
|
$2.02 M
|
$1.99 M
|
$1.18 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
